Chongqing Genrix

Genrix Bio introduces a domestically developed bispecific antibody targeting BCMA and CD3, offering a new treatment for patients with relapsed or refractory multiple myeloma. The therapy represents a significant advancement in China’s biopharmaceutical sector, addressing unmet needs in oncology. This marks the first domestically produced bispecific antibody of its kind in the country.

Nov 2026chinadaily.com.cnNews article

Cullinan Therapeutics advances **velinotamig** into global clinical trials for treating autoimmune cytopenias after receiving Investigational New Drug (IND) clearance from the U.S. FDA. The company assumes full development responsibility following the completion of the **Genrix Bio Phase 1 study**. Velinotamig targets autoimmune blood disorders, marking a key step in its clinical progression.

Oct 2026BioSpaceNews article

China’s National Medical Products Administration (NMPA) conditionally approves **GenrixBio’s velinotamig**, a bispecific T-cell-engaging antibody targeting **BCMA on myeloma cells and CD3 on T cells**, for use in **heavily pretreated multiple myeloma** patients. The approval marks a milestone for GenrixBio’s first therapeutic candidate, offering a new treatment option in a challenging patient population.

Aug 20261stoncology.comNews article

Cullinan Therapeutics acquires a BCMAxCD3 bispecific T-cell engager for an upfront payment of $20 million. The company intends to combine this asset with its existing CD19-focused candidate. The deal is part of a broader $700 million pact aimed at advancing immuno-oncology therapies.

Jun 2025Fierce BiotechNews article